Published in Trends Cardiovasc Med on November 01, 2007
Diabetic conditions promote binding of monocytes to vascular smooth muscle cells and their subsequent differentiation. Am J Physiol Heart Circ Physiol (2009) 1.63
Lowering dietary linoleic acid reduces bioactive oxidized linoleic acid metabolites in humans. Prostaglandins Leukot Essent Fatty Acids (2012) 1.09
Hydroxyoctadecadienoic acids: novel regulators of macrophage differentiation and atherogenesis. Ther Adv Endocrinol Metab (2010) 1.06
Homocysteine, Paraoxonase-1 and Vascular Endothelial Dysfunction: Omnibus viis Romam Pervenitur. J Clin Diagn Res (2014) 0.87
Hydrogen sulfide inhibits the development of atherosclerosis with suppressing CX3CR1 and CX3CL1 expression. PLoS One (2012) 0.86
Peroxisome proliferator-activated receptor agonists modulate neuropathic pain: a link to chemokines? Front Cell Neurosci (2014) 0.85
Nutraceuticals as Ligands of PPARγ. PPAR Res (2012) 0.84
The downstream regulation of chemokine receptor signalling: implications for atherosclerosis. Mediators Inflamm (2013) 0.83
Regulation of atherogenesis by chemokines and chemokine receptors. Arch Immunol Ther Exp (Warsz) (2012) 0.80
Atherogenic ω-6 Lipids Modulate PPAR- EGR-1 Crosstalk in Vascular Cells. PPAR Res (2011) 0.79
Oxidized metabolites of linoleic acid as biomarkers of liver injury in nonalcoholic steatohepatitis. Clin Lipidol (2013) 0.78
Atherosclerosis--an inflammatory disease. N Engl J Med (1999) 59.28
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity (2003) 21.56
The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature (1998) 13.58
Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature (2007) 11.59
The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med (2006) 10.99
PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature (1998) 10.09
PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell (1999) 10.08
Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest (2007) 9.09
Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature (1998) 8.92
A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet (1998) 8.02
PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell (1998) 7.91
A new class of membrane-bound chemokine with a CX3C motif. Nature (1997) 7.87
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med (2007) 7.86
Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell (1998) 7.46
International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev (2000) 7.17
Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A (2003) 6.82
The many faces of PPARgamma. Cell (2005) 6.24
Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature (2000) 5.86
The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol (1981) 5.86
Chemokines in the pathogenesis of vascular disease. Circ Res (2004) 4.64
Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A (1991) 4.56
Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med (1998) 4.16
The oxidation hypothesis of atherosclerosis. Lancet (1994) 4.10
Muscle-specific Pparg deletion causes insulin resistance. Nat Med (2003) 3.93
Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest (1991) 3.82
Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation (2003) 3.55
MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest (1999) 3.21
Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest (2003) 3.19
Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol (2002) 3.02
Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A (1998) 2.93
Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem (2001) 2.91
Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood (2001) 2.87
Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest (2000) 2.67
Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res (2001) 2.33
Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest (2003) 2.27
Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation (2000) 2.15
Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev (2004) 2.04
Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proc Natl Acad Sci U S A (2004) 2.00
Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med (1998) 1.93
Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (1999) 1.86
Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res (2005) 1.80
The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol (2003) 1.80
CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation (2005) 1.76
Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis (2001) 1.72
Chemokine receptor (CCR2) genotype is associated with myocardial infarction and heart failure in patients under 65 years of age. J Mol Med (Berl) (2003) 1.63
Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol (2004) 1.51
Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol (2005) 1.50
Control of monocyte recruitment by chemotactic factor(s) in lesion-prone areas of swine aorta. Arteriosclerosis (1985) 1.42
Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol (2002) 1.41
Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun (2000) 1.38
Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol (2003) 1.18
Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun (2000) 1.17
Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma. J Clin Invest (2000) 1.16
Transmembrane chemokines: versatile 'special agents' in vascular inflammation. Thromb Haemost (2007) 1.16
Enhanced adhesive capacities of the naturally occurring Ile249-Met280 variant of the chemokine receptor CX3CR1. J Biol Chem (2004) 1.15
Strong increase in hydroxy fatty acids derived from linoleic acid in human low density lipoproteins of atherosclerotic patients. Chem Phys Lipids (1998) 1.13
Transplantation of monocyte CC-chemokine receptor 2-deficient bone marrow into ApoE3-Leiden mice inhibits atherogenesis. Arterioscler Thromb Vasc Biol (2003) 1.13
Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation (2006) 1.12
Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial. Arterioscler Thromb Vasc Biol (2006) 1.07
Localisation of mRNA for JE/MCP-1 and its receptor CCR2 in atherosclerotic lesions of the ApoE knockout mouse. J Vasc Res (2000) 1.06
Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis. Annu Rev Pharmacol Toxicol (2006) 1.05
OxLDL upregulates CXCR2 expression in monocytes via scavenger receptors and activation of p38 mitogen-activated protein kinase. Cardiovasc Res (2002) 0.90
Peroxisome proliferator-activated receptor-alpha,gamma-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice. Arterioscler Thromb Vasc Biol (2006) 0.86
Lipids of human atheroma. 8. Oxidised derivatives of cholesteryl linoleate. Biochim Biophys Acta (1973) 0.85
Internal carotid artery occlusive disease and polymorphisms of fractalkine receptor CX3CR1: a genetic risk factor. Stroke (2004) 0.83
Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. Am J Cardiovasc Drugs (2006) 0.83
The occurrence of peroxidized lipids in atheromatous human aortas. Experientia (1951) 0.78
International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev (2009) 3.65
CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med (2006) 3.57
Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation (2003) 3.55
Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med (2005) 3.08
Formyl-peptide receptors revisited. Trends Immunol (2002) 3.08
CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J Infect Dis (2010) 2.72
Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis (2008) 2.54
Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest (2003) 2.27
International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev (2013) 2.11
CX3CR1-dependent renal macrophage survival promotes Candida control and host survival. J Clin Invest (2013) 2.00
Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol (2002) 1.98
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96
Organ-specific innate immune responses in a mouse model of invasive candidiasis. J Innate Immun (2010) 1.94
Chemokine receptor CX3CR1 mediates skin wound healing by promoting macrophage and fibroblast accumulation and function. J Immunol (2008) 1.90
Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog (2009) 1.81
CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation (2005) 1.76
Role for CCR5Delta32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells. J Virol (2004) 1.72
A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood (2014) 1.66
The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood (2011) 1.65
Chemokine receptor Ccr2 is critical for monocyte accumulation and survival in West Nile virus encephalitis. J Immunol (2010) 1.58
Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasis. PLoS Pathog (2012) 1.49
Complete genome sequence of a tenth human polyomavirus. J Virol (2012) 1.48
Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol (2004) 1.45
Distinct mechanisms of agonist-induced endocytosis for human chemokine receptors CCR5 and CXCR4. Mol Biol Cell (2003) 1.44
Chemokine regulation of inflammation during acute viral infection. Curr Opin Allergy Clin Immunol (2003) 1.42
Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction. J Am Soc Nephrol (2004) 1.41
Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. Blood (2006) 1.41
On the mechanism and significance of ligand-induced internalization of human neutrophil chemokine receptors CXCR1 and CXCR2. J Biol Chem (2004) 1.34
Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology (2003) 1.34
Identification of formyl peptides from Listeria monocytogenes and Staphylococcus aureus as potent chemoattractants for mouse neutrophils. J Immunol (2008) 1.30
CXCR4-transgene expression significantly improves marrow engraftment of cultured hematopoietic stem cells. Stem Cells (2004) 1.29
Enhanced function with decreased internalization of carboxy-terminus truncated CXCR4 responsible for WHIM syndrome. Exp Hematol (2005) 1.28
Chemokine receptor CX3CR1 regulates renal interstitial fibrosis after ischemia-reperfusion injury. Am J Pathol (2006) 1.26
Chemotaxis and calcium responses of phagocytes to formyl peptide receptor ligands is differentially regulated by cyclic ADP ribose. J Immunol (2004) 1.22
CCR5: no longer a "good for nothing" gene--chemokine control of West Nile virus infection. Trends Immunol (2006) 1.20
Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease. J Am Soc Nephrol (2005) 1.19
Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis. Blood (2010) 1.17
Impaired glucose homeostasis, neutrophil trafficking and function in mice lacking the glucose-6-phosphate transporter. Hum Mol Genet (2003) 1.15
AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome. J Cell Mol Med (2011) 1.14
Activation of cutaneous protein kinase C alpha induces keratinocyte apoptosis and intraepidermal inflammation by independent signaling pathways. J Immunol (2003) 1.13
Reduced cell surface expression of CCR5 in CCR5Delta 32 heterozygotes is mediated by gene dosage, rather than by receptor sequestration. J Biol Chem (2001) 1.13
Fractalkine mediates natural killer-dependent antitumor responses in vivo. Cancer Res (2003) 1.12
ApoB-containing lipoproteins regulate angiogenesis by modulating expression of VEGF receptor 1. Nat Med (2012) 1.12
Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression. Int J Cancer (2006) 1.10
Chemokine regulation of atherosclerosis. J Leukoc Biol (2007) 1.08
Intraluminal containment of commensal outgrowth in the gut during infection-induced dysbiosis. Cell Host Microbe (2013) 1.08
F2L, a peptide derived from heme-binding protein, chemoattracts mouse neutrophils by specifically activating Fpr2, the low-affinity N-formylpeptide receptor. J Immunol (2007) 1.08
IL-10 limits parasite burden and protects against fatal myocarditis in a mouse model of Trypanosoma cruzi infection. J Immunol (2011) 1.08
Chemokine receptor CCR1 regulates inflammatory cell infiltration after renal ischemia-reperfusion injury. J Immunol (2008) 1.06
Chemokine receptor CCR1 disruption in bone marrow cells enhances atherosclerotic lesion development and inflammation in mice. Mol Med (2006) 1.03
Atherogenic lipids induce adhesion of human coronary artery smooth muscle cells to macrophages by up-regulating chemokine CX3CL1 on smooth muscle cells in a TNFalpha-NFkappaB-dependent manner. J Biol Chem (2007) 0.99
Formylpeptide receptor-2 contributes to colonic epithelial homeostasis, inflammation, and tumorigenesis. J Clin Invest (2013) 0.99
Formylpeptide receptors are critical for rapid neutrophil mobilization in host defense against Listeria monocytogenes. Sci Rep (2012) 0.98
Bone marrow-derived cells require a functional glucose 6-phosphate transporter for normal myeloid functions. J Biol Chem (2006) 0.97
Genetic deletion of chemokine receptor Ccr6 decreases atherogenesis in ApoE-deficient mice. Circ Res (2011) 0.96
WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4. Blood (2012) 0.96
Chemokine control of West Nile virus infection. Exp Cell Res (2011) 0.95
CXCL12 signaling is independent of Jak2 and Jak3. J Biol Chem (2004) 0.95
Host chemokines bind to Staphylococcus aureus and stimulate protein A release. J Biol Chem (2010) 0.93
A divergent variant of the eleventh human polyomavirus species, saint louis polyomavirus. Genome Announc (2013) 0.92
SOCS3 negatively regulates the gp130-STAT3 pathway in mouse skin wound healing. J Invest Dermatol (2008) 0.91
Antimicrobial chemokines. Front Immunol (2012) 0.90
Defective antitumor responses in CX3CR1-deficient mice. Int J Cancer (2007) 0.90
Alanine scanning mutagenesis of the chemokine receptor CCR3 reveals distinct extracellular residues involved in recognition of the eotaxin family of chemokines. Mol Immunol (2005) 0.88
Cyclophilin A cooperates with MIP-2 to augment neutrophil migration. J Inflamm Res (2011) 0.86
Genetic deletion of chemokine receptor Ccr7 exacerbates atherogenesis in ApoE-deficient mice. Cardiovasc Res (2012) 0.86
The loss of RGS protein-Gα(i2) interactions results in markedly impaired mouse neutrophil trafficking to inflammatory sites. Mol Cell Biol (2012) 0.86
The N-formylpeptide receptor (FPR) and a second G(i)-coupled receptor mediate fMet-Leu-Phe-stimulated activation of NADPH oxidase in murine neutrophils. Cell Immunol (2002) 0.86
Roles of chemokines in renal ischemia/reperfusion injury. Front Biosci (2008) 0.85
Atherogenic lipids induce high-density lipoprotein uptake and cholesterol efflux in human macrophages by up-regulating transmembrane chemokine CXCL16 without engaging CXCL16-dependent cell adhesion. J Immunol (2009) 0.85
Intra-neural administration of fractalkine attenuates neuropathic pain-related behaviour. J Neurochem (2008) 0.84
The carboxyl terminus of the chemokine receptor CCR3 contains distinct domains which regulate chemotactic signaling and receptor down-regulation in a ligand-dependent manner. Eur J Immunol (2005) 0.83
The chemokine receptor CCR1 is strongly up-regulated after skin injury but dispensable for wound healing. Wound Repair Regen (2004) 0.83
IL-15 and IL-2 oppositely regulate expression of the chemokine receptor CX3CR1. Blood (2003) 0.83
Helix 8 of the viral chemokine receptor ORF74 directs chemokine binding. J Biol Chem (2006) 0.83
Interleukin (IL)-15 and IL-2 reciprocally regulate expression of the chemokine receptor CX3CR1 through selective NFAT1- and NFAT2-dependent mechanisms. J Biol Chem (2004) 0.82
Human neutrophil chemotaxis is modulated by capsule and O antigen from an extraintestinal pathogenic Escherichia coli strain. Infect Immun (2003) 0.81
Improved antibacterial host defense and altered peripheral granulocyte homeostasis in mice lacking the adhesion class G protein receptor CD97. Infect Immun (2006) 0.81
Regulation of atherogenesis by chemokines and chemokine receptors. Arch Immunol Ther Exp (Warsz) (2012) 0.80
Autosomal dominant epidermodysplasia verruciformis lacking a known EVER1 or EVER2 mutation. Pediatr Dermatol (2009) 0.80
CCR1 deficiency increases susceptibility to fatal coronavirus infection of the central nervous system. Viral Immunol (2007) 0.80
Characterization of Fpr-rs8, an atypical member of the mouse formyl peptide receptor gene family. J Innate Immun (2011) 0.79
Simian cytomegalovirus encodes five rapidly evolving chemokine receptor homologues. Virus Genes (2004) 0.78
IL-15 alters expression and function of the chemokine receptor CX3CR1 in human NK cells. Cell Immunol (2004) 0.78
The leukocyte chemotactic receptor FPR1 is functionally expressed on human lens epithelial cells. J Biol Chem (2012) 0.77
Regulation of motor function and behavior by atypical chemokine receptor 1. Behav Genet (2014) 0.77
Role of C-C chemokine receptors 1 and 5 and CCL3/macrophage inflammatory protein-1alpha in the cutaneous Arthus reaction: possible attenuation of their inhibitory effects by compensatory chemokine production. Eur J Immunol (2004) 0.77
Regulation of atherogenesis by chemokine receptor CCR6. Trends Cardiovasc Med (2011) 0.77
The major leukocyte chemotactic and activating factors in the mouse gut lumen are not N-formylpeptide receptor 1 agonists. J Innate Immun (2012) 0.76
Reduced fear memory and anxiety-like behavior in mice lacking formylpeptide receptor 1. Behav Genet (2011) 0.75
Hyperventilation as a simple cure for severe exercise-associated muscle cramping. Pain Med (2011) 0.75